Byoma taps skin longevity trend with new Longevit-8 Peptide Serum

Beauty’s shift from correcting visible signs of ageing to preserving skin health over time is gathering pace, with Byoma becoming the latest brand to target the longevity trend.

The Scottish skincare brand has launched Longevit-8 Peptide Serum, a £21.99 daily formula designed to support skin function while protecting the skin barrier. It is described as Byoma’s most advanced formula to date and is intended to address damage before it becomes visible.

The development comes as Lookfantastic’s AW26 Trend Report recorded a 4.7% quarter-on-quarter increase in searches for longevity-related skincare. The movement centres on prevention, regeneration and resilience, rather than focusing solely on reversing visible signs of ageing.

Meanwhile, Oriflame recently published a new white paper examining how longevity science is moving towards supporting skin function throughout life.

Launching today, 9 September, Longevit-8 is powered by a proprietary GHK-Cu Longevity Matrix, developed after Byoma tested nine combinations of longevity-focused molecules in vitro. The matrix combines copper tripeptide, vitamin E and niacinamide, supported by Phyto-PDRN, NMN, Argireline, Matrixyl 3000 and the brand’s Tri-Ceramide Complex.

Byoma said its oil-in-water delivery system uses glycols to carry water-based actives through the barrier while replenishing essential lipids. The approach is designed to maintain barrier integrity rather than temporarily increasing skin permeability.

According to company testing, the serum boosted natural collagen by 225% and delivered 1.76 times greater collagen-boosting efficacy than retinal. Byoma also reported improvements across eight visible signs of ageing, including firmness, wrinkle depth, elasticity and hydration. It said 96% of subjects achieved a strengthened skin barrier.

The brand also commissioned a placebo-controlled, 12-week study with Mark Birch-Machin, Professor of Molecular Dermatology, examining mitochondrial DNA damage. Byoma said the serum protected mitochondrial DNA in skin under 40 and reduced existing damage in skin over 40. The findings are being submitted for peer review.

“Our ambition is to take that level of evidence out of the lab, away from prestige price points and make it accessible to everyone,” said Byoma founder and CEO Marc Elrick.

Elrick has previously outlined Byoma’s investment in clinical testing, including an internal laboratory at its Glasgow headquarters. The brand said it has now conducted 120 clinical studies and analysed more than 157,000 individual skin measurements.

Founded in 2022, Byoma is a barrier-first skin health brand focused on making science-backed skincare more affordable and accessible. The company said it now sells one product every second globally and has more than two million social media followers.

Read TheIndustry.beauty's interview with Marc Elrick, founder & CEO of Byoma.